Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -30.70% is 36% above its 5-year average of -48.05%, near the high end of its 5-year range (-79.61%–-26.39%).
39.66% above its 12-month average of -50.88%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.00%.
RETURN ON ASSETS (ROA)
-30.70%
RETURN ON ASSETS (ROA) AVG TTM
-50.88%
RETURN ON ASSETS (ROA) AVG 3Y
-51.94%
RETURN ON ASSETS (ROA) AVG 5Y
-48.05%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.66%
CURRENT VS 3Y AVG
+40.89%
CURRENT VS 5Y AVG
+36.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.08%
median of 667 covered companies
CURRENT VS SECTOR MEDIAN
-2.06%
vs the sector median at left
Equillium, Inc.
Market Cap
$92.31M
Return on Assets (ROA)
-30.70%
TTM Avg
-50.88%
3Y Avg
-51.94%
5Y Avg
-48.05%
Market Cap
$89.06M
Return on Assets (ROA)
-91.66%
TTM Avg
-48.70%
3Y Avg
-37.97%
5Y Avg
-29.79%
Market Cap
$92.05M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$91.51M
Return on Assets (ROA)
-86.56%
TTM Avg
-66.44%
3Y Avg
-84.84%
5Y Avg
-75.69%
Market Cap
$89.11M
Return on Assets (ROA)
1.69%
TTM Avg
-3.62%
3Y Avg
-6.49%
5Y Avg
-4.78%
Market Cap
$93.27M
Return on Assets (ROA)
-88.24%
TTM Avg
-139.34%
3Y Avg
-100.15%
5Y Avg
-71.92%
Market Cap
$96.58M
Return on Assets (ROA)
-1.90%
TTM Avg
1.32%
3Y Avg
1.93%
5Y Avg
1.93%
Market Cap
$94.24M
Return on Assets (ROA)
-169.86%
TTM Avg
-100.47%
3Y Avg
-69.80%
5Y Avg
-64.10%
Market Cap
$86.90M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Equillium, Inc. (EQ) | $92.31M | -30.70% | -50.88% | -51.94% | -48.05% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.06M | -91.66% | -48.70% | -37.97% | -29.79% |
| Conexeu Sciences Inc. (CNXU)vs › | $92.05M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $91.51M | -86.56% | -66.44% | -84.84% | -75.69% |
| ImmuCell Corporation (ICCC)vs › | $89.11M | 1.69% | -3.62% | -6.49% | -4.78% |
| Biomea Fusion, Inc. (BMEA)vs › | $93.27M | -88.24% | -139.34% | -100.15% | -71.92% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $96.58M | -1.90% | 1.32% | 1.93% | 1.93% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $94.24M | -169.86% | -100.47% | -69.80% | -64.10% |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 8.52% | 11.64% | -8.81% | -6.61% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.96M | -79.38% | 41.63% | -36.06% | -44.84% |
ROA
-30.7%
ROE
-32.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -70.24% |
| 2024-12-31 | -31.51% |
| 2023-12-31 | -26.39% |
| 2022-12-31 | -79.61% |
| 2021-12-31 | -45.64% |
| 2020-12-31 | -34.90% |
| 2019-12-31 | -46.05% |
| 2018-12-31 | -19.73% |
| 2017-12-31 | -31.63% |
